Pfizer Expands Vaccine Portfolio with Novavax Licensing Deal

Pfizer has licensed Novavax's Matrix-M adjuvant technology for up to two infectious disease vaccines, granting Pfizer non-exclusive worldwide rights and control over development and commercialization. The deal includes an upfront payment, potential future milestone payments, and tiered royalties linked to product sales, giving Pfizer additional tools to build its vaccine pipeline beyond COVID-19. This move creates another revenue lever for investors to monitor as future products using this technology move through development and into the market.